Patient-tailored medicine, Part one: the impact of race and genetics on medicine

One of the more controversial elements of advancing technology is the use of race and genetics to help create more specific types of medicines that will help combat diseases and conditions that appear to be more prevalent within certain races or ethnic groups than in others. Considering the history...

Full description

Saved in:
Bibliographic Details
Published in:Journal of health & life sciences law 2008-10, Vol.2 (1), p.1-36
Main Authors: Braff, Jeffrey P, Chatterjee, Biswajit, Hochman, Meredith, Kelton, Teresa, Kennington, Jessica, Kolavala, Chandana, Layman, Katherine, Parver, Corrine, Selby, Myra C, Washlick, John R, Wolf, Rebecca
Format: Article
Language:English
Subjects:
Clinical Trials as Topic
Continental Population Groups
Drug Design
Eugenics
Health administration
Humans
Pharmacogenetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the more controversial elements of advancing technology is the use of race and genetics to help create more specific types of medicines that will help combat diseases and conditions that appear to be more prevalent within certain races or ethnic groups than in others. Considering the history of discrimination and inadequate treatment of individuals on the bases of race and gender in the United States, there is justifiable concern that race or gender-based treatment could be used to legitimate discrimination. On the other hand, there is substantial proof that the current method of creating medicines for the general public is problematic and could prevent effective treatments from reaching the marketplace. Part One of this series addresses the relevance of genetic information, and how race and genetics have affected and may impact the development of medicines, pharmacogenomics, and personalized medicine in the United States. Part Two, which will appear in the next issue of the Journal of Health and Life Sciences Law, will focus on how personalized medicine may affect the American legal, regulatory, and legislative environment.
ISSN:1942-4736